Merck & Co., Inc. (NYSE:MRK) announced a deal to hand over its CGRP migraine drugs to Allergan PLC (NYSE:AGN) for $250 million, half of which is to be paid upfront in cash. Merck has been in the competition for migraine drugs for a noteworthy period but recently decided to leave the race to the others…